The identification of the three annotated lncRNAs LINC02418, Lnc-OR1D5-1 and Lnc-PXDN-3 discriminating the ERG-positive subtype of prostate cancer vs. others and the analysis of the co-expressed protein-coding genes and these lncRNAs revealed novel promising pharmacological targets in specific subtypes of prostate cancer. This evidence concerns the gene OR1D5 and prostate cancer.